Most insurance companies classify ketamine infusions as “experimental” or “investigational,” which means they won’t pay for them. This applies whether you’re seeking ketamine for depression, chronic pain, anxiety, or any other condition. The core reason is straightforward: generic ketamine has never been FDA-approved for psychiatric use, and insurers use that gap as their primary justification for denial.
The FDA Approval Gap
Ketamine was approved by the FDA in 1970 as an anesthetic for surgical procedures. When doctors administer it at lower doses for depression or chronic pain, that’s considered “off-label” use. Off-label prescribing is legal and common across medicine, but insurance companies are not required to cover off-label treatments, and most choose not to when it comes to ketamine.
This creates a frustrating paradox. There is substantial clinical evidence that ketamine works for treatment-resistant depression, often producing rapid improvement within hours. But because no pharmaceutical company has pursued (or has financial incentive to pursue) FDA approval for generic ketamine as a psychiatric treatment, insurers treat it as unproven. In a 2023 case reviewed by Michigan’s insurance regulator, Blue Care Network denied coverage by stating that intravenous ketamine “has not been scientifically demonstrated to improve patient clinical outcomes” and that “there is still much that isn’t known about dosing, frequency of treatment, and duration of treatment.”
What Insurers Specifically Say
The language in insurance policy documents is remarkably consistent across companies. Aetna’s clinical policy bulletin considers ketamine “experimental, investigational, or unproven” for depression, chronic pain, and a long list of other conditions, regardless of how it’s administered: IV, intramuscular, intranasal, oral, or subcutaneous. This blanket classification covers essentially every form of generic ketamine therapy.
Insurers point to three main concerns to justify these denials. First, the lack of FDA approval for psychiatric or pain indications. Second, the absence of standardized treatment protocols, meaning there’s no widely agreed-upon dosing schedule or treatment duration. Third, the lack of a formal risk management program like the one required for Spravato (more on that below). These aren’t fringe positions held by one or two insurers. They represent the standard stance across most commercial insurance plans.
Spravato Is Different, but Barely
Esketamine, sold as Spravato, is a nasal spray that uses a close chemical relative of ketamine. It is FDA-approved for two specific conditions: treatment-resistant depression in adults, and depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior. Because it has FDA approval, insurance companies are more likely to cover it, but the approval process comes with significant strings attached.
To qualify for Spravato coverage through a plan like Aetna’s, you typically need to show that at least two different antidepressants from different drug classes failed to help you, each taken at the maximum tolerable dose for at least eight weeks within the past five years. On top of that, you generally need to have tried augmentation therapy (adding a second medication to boost the first) for at least eight weeks, or completed a course of evidence-based psychotherapy like cognitive behavioral therapy. These step-therapy requirements mean months or years of documented treatment failure before coverage kicks in.
Spravato also must be administered in a certified healthcare setting where you’re monitored for at least two hours after each dose. You can’t take it home. This adds logistical barriers that IV ketamine clinics don’t have, but it’s also part of why insurers are willing to cover it: the controlled environment satisfies their risk management concerns.
Pain Coverage Isn’t Better
If you’ve heard that ketamine is more likely to be covered when used for chronic pain conditions like complex regional pain syndrome (CRPS) or fibromyalgia, that’s largely outdated. Aetna’s current policy explicitly lists chronic pain alongside depression as an indication it considers experimental. The same “investigational” label applies. While individual cases and plans vary, the broad trend among major insurers is to deny coverage for ketamine across both psychiatric and pain indications.
Out-of-Network Reimbursement
Some ketamine clinics suggest that patients pay out of pocket and then submit a “superbill” to their insurance company for out-of-network reimbursement. A superbill is essentially a detailed receipt with medical billing codes that you send to your insurer yourself, requesting partial repayment. In practice, this route has limited success.
The billing codes used for ketamine infusions are standard IV therapy codes, and the evaluation and management codes for your doctor’s time tend to carry more reimbursement value than the infusion itself. The drug code for ketamine often reimburses just a dollar or two, if anything. Some clinics don’t even include the drug code on superbills because it can trigger extra scrutiny without meaningful payback. Clinics that help patients with this process are careful to avoid promising results. Reimbursement is not guaranteed, and many payers will simply reject the claim once they identify the treatment as off-label ketamine.
If your insurance plan has out-of-network benefits, you may recover a portion of the office visit cost, but expecting meaningful reimbursement for the ketamine treatment itself is unrealistic for most patients.
What You’ll Actually Pay
Without insurance, a single ketamine infusion for depression typically costs between $400 and $800, and an initial treatment course usually involves six infusions over two to three weeks. That puts the upfront cost somewhere between $2,400 and $4,800 for the initial series alone. Maintenance infusions, often needed every few weeks to months, add ongoing costs. Oral ketamine prescribed through telehealth services tends to be cheaper, often $150 to $300 per month, but carries the same lack of insurance coverage.
Spravato, when covered by insurance, shifts most of the cost to the insurer, though copays and coinsurance can still be significant. The manufacturer offers a savings program for commercially insured patients, which can reduce out-of-pocket costs. If you can meet the step-therapy requirements and your plan covers Spravato, it’s typically the most financially accessible option for ketamine-related treatment.
State-Level Exceptions
A small number of state Medicaid programs have begun covering IV ketamine for specific psychiatric conditions. Wisconsin’s Medicaid program, for example, has established specific billing procedures for IV ketamine infusion therapy for major depressive disorder with or without suicidality, requiring providers to use designated billing codes and modifiers. These programs remain exceptions rather than the rule, and coverage criteria vary significantly by state. If you’re on Medicaid, it’s worth checking your state’s current policy directly rather than assuming denial.
For most people with commercial insurance, the situation remains unchanged: generic ketamine for depression or pain is classified as experimental, and the insurer won’t pay. The gap between clinical evidence and insurance policy is real, driven primarily by the absence of FDA approval for these specific uses and the lack of standardized treatment guidelines that insurers require before reclassifying a treatment as medically necessary.